| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -81,679 | -57,366 |
| Depreciation | 1,561 | 1,060 |
| Stock-based compensation | 30,706 | 21,662 |
| Accretion of discounts on investments, net | 14,050 | 9,427 |
| Prepaid expenses and other current assets | 600 | 1,049 |
| Accounts receivable | - | 0 |
| Other long-term assets | -257 | -191 |
| Accounts payable | -692 | -524 |
| Accrued expenses | 10,806 | 4,627 |
| Deferred revenue | 0 | 0 |
| Operating lease right-of-use assets and liabilities, net | 2 | 11 |
| Net cash used in operating activities | -53,693 | -40,837 |
| Purchases of property and equipment | 937 | 844 |
| Purchases of short-term investments | 581,945 | 463,976 |
| Maturities of short-term investments | 252,358 | 125,990 |
| Net cash used in investing activities | -330,524 | -338,830 |
| Proceeds from exercise of common stock options and employee stock purchase plan | 2,348 | 1,855 |
| Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs | -347 | -347 |
| Net cash provided by financing activities | 2,001 | 1,508 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -382,216 | -378,159 |
| Cash and cash equivalents at beginning of period | 431,421 | - |
| Cash and cash equivalents at end of period | 49,205 | - |
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)